EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Molecular architecture responsible for specific inhibition of oncogenic PI3Kα mutants by RLY-2608 and STX-478

Xiao Liu, Yanyan Chen, Guanyi Li, Anqi Chen, Qingtong Zhou, Ming-Wei Wang

Acta Pharmaceutica Sinica B · 2026-09 · 16 (9) · 5884-5900

DOI: 10.1016/j.apsb.2026.07.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2026-09. Verfasst von Xiao Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China National Outstanding Youth Science Fund Project, National Natural Science Foundation of China, Hainan Provincial Postdoctoral Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hotspot mutations in phosphoinositide 3-kinase alpha (PI3Kα), such as H1047R, E542K, and E545K, drive tumorigenesis across multiple cancer types. Orthosteric PI3Kα inhibitors are effective but have toxicity against wild-type PI3Kα, the emergence of resistance, and a narrow therapeutic index. Allosteric inhibitors such as RLY-2608 and STX-478 offer a promising path toward mutant-specific suppression, yet the structural basis for their selectivity and mechanisms of action remain elusive. Here, we report high-resolution cryogenic electron microscopy structures of RLY-2608- and STX-478-bound H1047R, E542K, and E545K, revealing a shared cryptic allosteric pocket, accessible only through a major conformational rearrangement of the activation loop that is stabilized in oncogenic mutants. While both inhibitors occupy this pocket, they have distinct interaction networks and propagate divergent allosteric activities: RLY-2608 induces large-scale remodeling of catalytic and membrane-interacting elements, whereas STX-478 reinforces autoinhibitory interfaces between p110α and p85α subunits. Comparative analysis provides structural insights into their differentiated potency and selectivity.

Schlagwörter

Stichwörter der Autor:innen

CancerInhibitorMutationPI3KαSelectivity

Autor:innen und Institutionen

  • Department of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
  • Research Center for Deepsea Bioresources, Sanya 572025, China.
  • Research Center for Medicinal Structural Biology, National Research Center for Translational Medicine at Shanghai, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medic…
  • Engineering Research Center of Tropical Medicine Innovation and Transformation of Ministry of Education, School of Pharmacy, Hainan Medical University, Haikou 570228, China.
  • Department of Chemistry, School of Science, The University of Tokyo, Tokyo 113-0033, Japan.

Förderung

  • National Natural Science Foundation of China National Outstanding Youth Science Fund Project
  • National Natural Science Foundation of China
  • Hainan Provincial Postdoctoral Science Foundation

Zitieren

APA

Liu, X., Chen, Y., Li, G., Chen, A., Zhou, Q., & Wang, M. W. (2026). Molecular architecture responsible for specific inhibition of oncogenic PI3Kα mutants by RLY-2608 and STX-478. Acta Pharmaceutica Sinica B, 16(9), 5884-5900. https://doi.org/10.1016/j.apsb.2026.07.003

Vancouver

Liu X, Chen Y, Li G, Chen A, Zhou Q, Wang MW. Molecular architecture responsible for specific inhibition of oncogenic PI3Kα mutants by RLY-2608 and STX-478. Acta Pharmaceutica Sinica B. 2026;16(9):5884-5900. doi:10.1016/j.apsb.2026.07.003

BibTeX
@article{Liu2026,
  author = {Liu, Xiao and Chen, Yanyan and Li, Guanyi and Chen, Anqi and Zhou, Qingtong and Wang, Ming-Wei},
  title = {Molecular architecture responsible for specific inhibition of oncogenic PI3Kα mutants by RLY-2608 and STX-478},
  journal = {Acta Pharmaceutica Sinica B},
  year = {2026},
  volume = {16},
  number = {9},
  pages = {5884--5900},
  doi = {10.1016/j.apsb.2026.07.003}
}
Kostenlos starten →